Efficacy and tolerability of first-line treatment regimens for extensive-stage small cell lung cancer - a grade-assessed network meta-analysis of randomized controlled trials - PubMed
3 hours ago
- #immunotherapy
- #small-cell lung cancer
- #network meta-analysis
- The study evaluates first-line treatments for extensive-stage small-cell lung cancer (ES-SCLC), focusing on efficacy and tolerability.
- Immunotherapy-based regimens like Serplulimab + EP, Atezolizumab + EP, and Durvalumab + EP showed significant improvements in overall survival (OS) compared to standard Etoposide plus platinum (EP).
- Serplulimab + EP provided the greatest benefit in progression-free survival (PFS), while Irinotecan + platinum significantly improved the complete response rate (CRR).
- Safety outcomes varied, with some immunotherapy combinations showing lower risks of treatment discontinuation and others associated with increased risks of serious adverse events (AEs).
- The study concludes that immunotherapy-based combinations, particularly Serplulimab + EP, offer improved survival outcomes with an acceptable safety profile, though some regimens have higher AE risks.